Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.

In this population with a more severe CKD, dapagliflozin vs placebo showed no differences regarding the incidence of the secondary endpoint “worsening renal function,” a composite of sustained ≥ 50% reduction in eGFR, ESRD, or death from renal causes (HR 0.71; 95% CI 0.44–1.16, p = 0.17) but showed a trend of benefit for dapagliflozin group (worsening renal function occurred in 1.2% of the dapagliflozin group vs 1.6% of controls) [ 58 ].

also in 53,322 other papers